FIELD: biotechnology.
SUBSTANCE: invention refers to biotechnology and molecular biology. Disclosed is use of virion of recombinant adeno-associated virus (rAAV), which contains polynucleotide, which codes soluble protein, which contains a VEGFR-1 (Flt-1) domain, capable of modulating VEGF activity, when preparing a composition for treating macular degeneration in a human subject by delivery of not more than 2 × 109 rAAV virions to the eye of a subject suffering from said disease.
EFFECT: invention can be used for treating in ophthalmology.
53 cl, 16 dwg, 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| FUSED PROTEINS CONTAINING PDGF AND VEGF BINDING PARTS, AND METHODS FOR USE THEREOF | 2014 |
|
RU2692652C2 |
| ADENO-ASSOCIATED VIRAL VECTORS FOR TREATMENT OF MYOCILIN (MYOC) GLAUCOMA | 2015 |
|
RU2746991C2 |
| ADENO-ASSOCIATED VIRUS VECTORS FOR TREATING MYOCILIN (MYOC) GLAUCOMA | 2015 |
|
RU2718047C2 |
| VIRIONS OF AN ADENO-ASSOCIATED VIRUS WITH A VARIANT CAPSID AND METHODS FOR USING THEM | 2017 |
|
RU2742724C1 |
| VIRIONS OF ADENO-ASSOCIATED VIRUS WITH OPTIONAL CAPSID AND METHODS OF THEIR USE | 2012 |
|
RU2611202C2 |
| RNAi AGENT OPTION | 2018 |
|
RU2789647C2 |
| GENE EDITING OF DEEP INTRON MUTATIONS | 2016 |
|
RU2759335C2 |
| GENE THERAPY OF OPHTHALMIC DISORDERS | 2016 |
|
RU2762747C2 |
| METHODS FOR AAV DETECTION | 2017 |
|
RU2771622C2 |
| TREATMENT OF COMPLEMENT-MEDIATED DISORDERS | 2017 |
|
RU2768982C2 |
